Search results for "risk assessment."

showing 10 items of 1342 documents

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

2022

AimsTyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverseevents. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have beenused to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulnessof the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Associ-ation (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular riskin CML patients, compared with SCORE risk charts. The secondary aim was to establish…

AdultHeart FailureMaleAspirinMiddle AgedRisk AssessmentCardio-oncology Cardiovascular prevention Chronic myeloid leukaemia Nilotinib Ponatinib Cardiovascular toxicityCardiotoxicityInducible T-Cell Co-Stimulator ProteinLeukemia Myelogenous Chronic BCR-ABL PositiveChronic DiseaseHumansFemaleCardiology and Cardiovascular MedicineAgedRetrospective StudiesESC Heart Failure
researchProduct

Is ‘anxiety sensitivity’ predictive of postoperative nausea and vomiting?

2019

BACKGROUND Postoperative nausea and vomiting (PONV) is an extremely distressing side effect for patients. Despite PONV prophylaxis guided by well established scoring systems, the incidence of PONV is still high. OBJECTIVE The aim of the current study was to investigate the predictive value of anxiety sensitivity as an additional independent risk factor for PONV in patients with an increased risk of PONV. DESIGN A noninterventional, observational study. SETTING A tertiary care university hospital. PATIENTS Patients with an increased risk of PONV (i.e. female, nonsmoking) undergoing elective surgery (general, gynaecological, urological, musculoskeletal or neurosurgical) under general anaesthe…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentAnesthesia GeneralAnxietyRisk AssessmentPredictive Value of TestsRisk FactorsInternal medicineHumansMedicineGeneral anaesthesiaProspective StudiesRisk factorElective surgeryAgedPsychological Testsbusiness.industryIncidenceAge FactorsOdds ratioMiddle AgedPrognosisAnesthesiology and Pain MedicineElective Surgical ProceduresPostoperative Nausea and VomitingAnxiety sensitivityAntiemeticsFeasibility StudiesFemaleObservational studymedicine.symptombusinessPostoperative nausea and vomitingEuropean Journal of Anaesthesiology
researchProduct

Are Adiponectin and Leptin Good Predictors of Surgical Infection after Colorectal Surgery? A Prospective Study

2015

Infections are the most frequent complication after colorectal surgery. It has been suggested that adipose tissue metabolism could be related to the risk of post-operative infection, but this could be partially related to the body-mass index. The aim of this study was to look for a relation between adipocytokine levels and the risk of post-operative infection and its type.This prospective cohort study was conducted between March 2013 and March 2014 in two French teaching hospitals. Pre-operative plasma levels of adiponectin and leptin were measured in consecutive patients undergoing elective colorectal surgery. All infections in the 30 d following surgery were recorded.Among the 142 patient…

AdultLeptinMaleMicrobiology (medical)medicine.medical_specialtyRisk AssessmentPlasmaInternal medicineHumansSurgical Wound InfectionMedicineProspective StudiesHospitals TeachingProspective cohort studyAgedAged 80 and overAdiponectinbusiness.industryLeptinMiddle AgedPrognosisColorectal surgerySurgeryInfectious DiseasesFemaleSurgeryAdiponectinFrancebusinessRisk assessmentComplicationColorectal SurgeryBody mass indexSurgical InfectionsSurgical Infections
researchProduct

Interaction of alcohol intake and cofactors on the risk of cirrhosis.

2010

OBJECTIVE: Evaluation of the interaction between alcohol intake and cofactors [hepatitis B virus (HBV), hepatitis C virus (HCV), body mass index] and coffee consumption on the risk of cirrhosis. DESIGN: Seven hundred and forty-nine consecutive patients with chronic liver disease referring to units for liver or alcohol diseases in Italy during a 6-months period. Teetotalers were excluded. The odds ratios (OR) for cirrhosis were evaluated using chronic hepatitis cases as the control group. RESULTS: An alcohol intake of more than 3 units/day resulted associated with the likelihood of cirrhosis both in males (OR 4.3; 95% CI=2.5-7.3) and in females (OR 5.7; 95% CI=2.3-14.5). A multiplicative int…

AdultLiver CirrhosisMaleHepatitis B virusAlcohol Drinkingalcohol cirrhosis coffeeHepacivirusCoffeeRisk Assessmentcirrhosis coffeeBody Mass IndexNORisk FactorsOdds RatioHumansCIRRHOSISAgedHepatitis B Surface AntigensalcoholHepatitis C AntibodiesMiddle AgedHepatitis BHepatitis CItalyCase-Control StudiesDisease ProgressionRNA ViralFemale
researchProduct

High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance

2004

The emergence of drug-resistant virus in hepatitis B virus patients treated with lamivudine is well documented. However. its clinical impact in the long-term treatment of anti-HBe positive compensated cirrhotic patients is not well known. In this study, we treated 22 consecutive patients with anti-HBe compensated cirrhosis with lamivudine for a median period of 42 months. All patients responded to lamivudine, but viral breakthrough occurred in 13 patients (59%) between 9 and 42 months of therapy due to the emergence of a mutant strain. During the follow-up, 11 developed hepatocellular carcinoma. Of these, 10 occurred soon after the emergence of viral resistance, generally showing aggressive…

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisLAMIVUDINEmedicine.disease_causeRisk AssessmentGastroenterologyVirusVirologyInternal medicineDrug Resistance ViralHumansMedicineHepatitis B e AntigensHEPATOCELLULAR CARCINOMAHepatitis B AntibodiesCIRRHOISIS; HEPATOCELLULAR CARCINOMA; LAMIVUDINE; HEPATITIS B; PRE-CORE MUTANTHepatitis B virusCirrhosiHepatologybusiness.industryCIRRHOISISLamivudineMiddle AgedHepatitis Bmedicine.diseaseHepatitis B Core AntigensViral BreakthroughPRE-CORE MUTANTInfectious DiseasesHepatocellular carcinomaRelative riskMutationHEPATITIS BReverse Transcriptase InhibitorsFemalePrecore mutantbusinessmedicine.drugJournal of Viral Hepatitis
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

2019

In patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is a risk factor for the development of fibrosis. However, fibrosis has been observed in livers of patients without NASH. We aimed to estimate the prevalence of fibrosis in patients without NASH and risk factors for fibrosis.We analyzed data from 1738 subjects (44.9% with severe obesity) in a cross-sectional liver biopsy cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histologically by a blinded pathologist at each center, and a diagnosis of NASH was made based on steatosis (≥5% of hepatocytes), hepatocellular ballooning, and lobular inflammation. We also c…

AdultLiver CirrhosisMalemedicine.medical_specialtyBiopsydigestive systemGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseBiopsymedicinePrevalenceHumansrisk factorsRisk factorhistory; inflammatory response; progression; risk factorsHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesinflammatory responsemedicine.diseasedigestive system diseasesFatty LiverCross-Sectional StudiesItalyLiver030220 oncology & carcinogenesisLiver biopsyCohort030211 gastroenterology & hepatologyFemalehistoryprogressionSteatohepatitisbusiness
researchProduct

Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study

2020

Bone fractures are a frequent complication in patients with cirrhosis. Proton pump inhibitors (PPIs) are among the most frequently prescribed medications and may impair bone quality and quantity.To investigate whether PPI use predisposes patients with cirrhosis to bone fractures.We performed a population-based case-control study exploring a sample of patients with cirrhosis derived from the Disease Analyzer database. In total, 1795 cirrhotic patients with fractures were compared to 10 235 cirrhotic patients without fractures. PPI use overall and the cumulative PPI dose 5 years prior to the index date were analysed. To estimate the association between PPI use and fractures, logistic regressi…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisAdolescentPopulationDiseaseLogistic regressionRisk AssessmentFractures BoneYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)030212 general & internal medicineYoung adulteducationAgedAged 80 and overeducation.field_of_studyHepatologybusiness.industryGastroenterologyCase-control studyProton Pump InhibitorsMiddle Agedmedicine.diseaseCase-Control StudiesFemale030211 gastroenterology & hepatologyRisk assessmentbusinessComplicationAlimentary Pharmacology & Therapeutics
researchProduct

Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study

2009

OBJECTIVES: The identification of prognostic factors associated with mortality is crucial in any clinical setting. METHODS: We enrolled in a prospective study 352 patients with compensated hepatitis C virus (HCV)-induced cirrhosis, consecutively observed between 1989 and 1992. At entry, patients underwent upper endoscopy to detect esophageal varices, and were then surveilled by serial clinical and ultrasonographic examination. The model for end-stage liver disease (MELD) score was calculated with information collected at enrollment. Baseline predictors and intercurrent events associated with mortality were assessed using the Cox regression model. RESULTS: During a median follow-up of 14.4 y…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsCirrhosisBiopsy Fine-NeedleKaplan-Meier EstimateEsophageal and Gastric VaricesAntiviral AgentsRisk AssessmentSeverity of Illness IndexGastroenterologyCohort StudiesPredictive Value of TestsCause of DeathInternal medicineEpidemiologyConfidence IntervalsmedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProbabilityProportional Hazards ModelsCause of deathSettore MED/12 - GastroenterologiaHepatologybusiness.industryGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseImmunohistochemistrySurvival Analysisliver cirrhosis natural historyDisease ProgressionFemalebusinessRisk assessmentLiver FailureFollow-Up StudiesCohort studyThe American Journal of Gastroenterology
researchProduct

RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit.

2009

Background and Aim: To evaluate the association of the Risk, Injury, Failure, Loss and End-stage renal failure (RIFLE) score on mortality in patients with decompensated cirrho- sis admitted to intensive care unit (ICU). Methods: A cohort of 412 patients with cirrhosis consecutively admitted to ICU was classified according to the RIFLE score. Multivariable logistic regression analysis was used to evaluate the factors associated with mortality. Liver-specific, Acute Physiology and Chronic Health Evaluation (APACHE) II, Sequential Organ Failure Assessment (SOFA) and RIFLE scores on admission, were compared by receiver-operator characteristic curves. Results: The overall mortality during ICU st…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsRisk AssessmentSensitivity and SpecificitySeverity of Illness Indexlaw.inventionHepatorenal syndromelawPredictive Value of TestsRisk FactorsInternal medicineCause of DeathEpidemiologymedicineHealth Status IndicatorsHumansRifleAPACHERetrospective StudiesHepatologybusiness.industryGastroenterologyAcute kidney injuryReproducibility of ResultsOdds ratioAPACHE cirrhosis intensive care unit MELD renal failure RIFLE SOFA.Acute Kidney InjuryMiddle Agedmedicine.diseasePrognosisIntensive care unitSurgeryIntensive Care UnitsLogistic ModelsROC CurveCohortFemalebusinessKidney disease
researchProduct